The Effect of Marrow Stromal Cells on TRAF6 Expression Levels in Myeloma Cells

Overview

Journal Oncol Lett

Specialty Oncology

Date 2017 Aug 10

PMID 28789366

Citations 3

Authors

Hongming Huang

Zhongwei Sun

Xudong Wang

Xinxin Liu

Wenxiu Na

Ruirong Xu

Runsheng Ding

Hong Liu

Affiliations

Soon will be listed here.

Abstract

Tumor necrosis factor receptor-associated factor 6 (TRAF6) is an important E3 ubiquitin ligase, which is key to immunity. TRAF6 has been implicated in the invasive growth and metastasis of various types of cancer, including squamous cell carcinoma, gastric cancer, myelodysplastic syndromes and acute myeloid leukemia. In the present study, associations between multiple myeloma (MM) and TRAF6, its downstream component nuclear factor-κB (NF-κB) and bone marrow stromal cells (MSC) were investigated. The TRAF6 protein expression levels of 18 patients were positively correlated with the protein levels of β-2 microglobulin (r=0.3472; P=0.01) and negatively correlated with albumin protein levels (r=0.5494; P=0.0004). expression of the TRAF6 protein, phosphorylated transcription factor p65 and phosphorylated p100 in myeloma cell lines was induced by MSCs from patients with MM. In addition, the expression of TRAF6 was associated with an enhanced proliferation rate of myeloma cells, which was blocked by silencing TRAF6 using small interfering RNA. Due to the association between the TRAF6-NF-κB signaling pathway in myeloma cells and MSCs, this signaling pathway may be a useful prognostic and therapeutic target in myeloma.

Citing Articles

Tumor Necrosis Factor Receptor-Associated Factor 6 and Human Cancer: A Systematic Review of Mechanistic Insights, Functional Roles, and Therapeutic Potential.

Li T, Lei Z, Wei L, Yang K, Shen J, Hu L J Cancer. 2024; 15(2):560-576.

PMID: 38169510 PMC: 10758021. DOI: 10.7150/jca.90059.

TRAF6 promotes osteogenesis in ADSCs through Raf-Erk-Merk-Hif1-a pathway.

Liu X, Zheng J, Song S, Chen Z, Wang Y, Zhang S Adipocyte. 2023; 12(1):2193280.

PMID: 37005742 PMC: 10072064. DOI: 10.1080/21623945.2023.2193280.

TRAF6 Silencing Attenuates Multiple Myeloma Cell Adhesion to Bone Marrow Stromal Cells.

Morgan J, McAvera R, Crawford L Int J Mol Sci. 2019; 20(3).

PMID: 30736330 PMC: 6387103. DOI: 10.3390/ijms20030702.

References

Annunziata C, Davis R, Demchenko Y, Bellamy W, Gabrea A, Zhan F . Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007; 12(2):115-30. PMC: 2730509. DOI: 10.1016/j.ccr.2007.07.004. View

Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S . Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood. 2009; 114(17):3625-8. PMC: 2766678. DOI: 10.1182/blood-2009-05-220285. View

Greipp P, San Miguel J, Durie B, Crowley J, Barlogie B, Blade J . International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15):3412-20. DOI: 10.1200/JCO.2005.04.242. View

Huang H, Wang X, Liu X, Xu R, Shi W, Ding R . [Effects of down-regulated TRAF6 gene expression on the proliferation and apoptosis in multiple myeloma cells]. Zhonghua Xue Ye Xue Za Zhi. 2013; 34(11):941-5. DOI: 10.3760/cma.j.issn.0253-2727.2013.11.007. View

Xu G, Liu K, Anderson J, Patrene K, Lentzsch S, Roodman G . Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation. Blood. 2012; 119(18):4205-14. PMC: 3359740. DOI: 10.1182/blood-2011-05-353300. View

Dimopoulos M, Barlogie B, Smith T, Alexanian R . High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med. 1991; 115(12):931-5. DOI: 10.7326/0003-4819-115-12-931. View

Hongming H, Jian H . Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6. Leuk Res. 2008; 33(1):115-22. DOI: 10.1016/j.leukres.2008.07.028. View

Gunn W, Conley A, Deininger L, Olson S, Prockop D, Gregory C . A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells. 2005; 24(4):986-91. DOI: 10.1634/stemcells.2005-0220. View

Armstrong A, Tometsko M, Glaccum M, Sutherland C, Cosman D, Dougall W . A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem. 2002; 277(46):44347-56. DOI: 10.1074/jbc.M202009200. View

10.

Kobayashi T, Walsh P, Walsh M, Speirs K, Chiffoleau E, King C . TRAF6 is a critical factor for dendritic cell maturation and development. Immunity. 2003; 19(3):353-63. DOI: 10.1016/s1074-7613(03)00230-9. View

11.

Abe M . Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma. Int J Hematol. 2011; 94(4):334-343. DOI: 10.1007/s12185-011-0949-x. View

12.

Sun Y, Ye Z, Qian Z, Xu X, Hu J . Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients. J Exp Clin Cancer Res. 2012; 31:81. PMC: 3523060. DOI: 10.1186/1756-9966-31-81. View

13.

Zhong L, Cao F, You Q . Effect of TRAF6 on the biological behavior of human lung adenocarcinoma cell. Tumour Biol. 2012; 34(1):231-9. DOI: 10.1007/s13277-012-0543-8. View

14.

Liu H, Tamashiro S, Baritaki S, Penichet M, Yu Y, Chen H . TRAF6 activation in multiple myeloma: a potential therapeutic target. Clin Lymphoma Myeloma Leuk. 2012; 12(3):155-63. PMC: 3799862. DOI: 10.1016/j.clml.2012.01.006. View

15.

Nagura E . [Prognositic factors in multiple myeloma]. Nihon Rinsho. 2007; 65(12):2351-6. View

16.

Rong Z, Cheng L, Ren Y, Li Z, Li Y, Li X . Interleukin-17F signaling requires ubiquitination of interleukin-17 receptor via TRAF6. Cell Signal. 2007; 19(7):1514-20. DOI: 10.1016/j.cellsig.2007.01.025. View

17.

Chaudhry S, Hooper S, Nye E, Williamson P, Harrington K, Sahai E . Autocrine IL-1β-TRAF6 signalling promotes squamous cell carcinoma invasion through paracrine TNFα signalling to carcinoma-associated fibroblasts. Oncogene. 2012; 32(6):747-58. PMC: 3446864. DOI: 10.1038/onc.2012.91. View

18.

Wu H, Arron J . TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology. Bioessays. 2003; 25(11):1096-105. DOI: 10.1002/bies.10352. View

19.

Theoleyre S, Wittrant Y, Tat S, Fortun Y, Redini F, Heymann D . The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004; 15(6):457-75. DOI: 10.1016/j.cytogfr.2004.06.004. View

20.

Kaneko M, Kanda Y, Oshima K, Nannya Y, Suguro M, Yamamoto R . Simple prognostic model for patients with multiple myeloma: a single-center study in Japan. Ann Hematol. 2002; 81(1):33-6. DOI: 10.1007/s00277-001-0388-5. View